Related Experiment Video
Updated: Jun 12, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
NADPH oxidase 1/4 dual inhibitor setanaxib suppresses platelet activation and thrombus formation
Eun Bee Oh1, Hye Ji Shin2, Hyunseong Yu1
1College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Aims:
The production of reactive oxygen species (ROS) by NADPH oxidase (NOX) is able to induce platelet activation, making NOX a promising target for antiplatelet therapy. In this study, we examined the effects of setanaxib, a dual NOX1/4 inhibitor, on human platelet function and ROS-related signaling pathways.
Materials And Methods:
In collagen-stimulated human platelets, aggregometry, assessment of ROS and Ca2+, immunoblotting, ELISA, flow cytometry, platelet adhesion assay, and assessment of mouse arterial thrombosis were performed in this study.
Key Findings:
Setanaxib inhibited both intracellular and extracellular ROS production in collagen-activated platelets. Additionally, setanaxib significantly inhibited collagen-induced platelet aggregation, P-selectin exposure from α-granule release, and ATP release from dense granules. Setanaxib blocked the specific tyrosine phosphorylation-mediated activation of Syk, LAT, Vav1, and Btk within collagen receptor signaling pathways, leading to reduced activation of PLCγ2, PKC, and Ca2+ mobilization. Setanaxib also inhibited collagen-induced activation of integrin αIIbβ3, which is linked to increased cGMP levels and VASP phosphorylation. Furthermore, setanaxib suppressed collagen-induced p38 MAPK activation, resulting in decreased phosphorylation of cytosolic PLA2 and reduced TXA2 generation. Setanaxib also inhibited ERK5 activation, affecting the exposure of procoagulant phosphatidylserine. Setanaxib reduced thrombus formation under shear conditions by preventing platelet adhesion to collagen. Finally, in vivo administration of setanaxib in animal models led to the inhibition of arterial thrombosis.
Significance:
This study is the first to show that setanaxib suppresses ROS generation, platelet activation, and collagen-induced thrombus formation, suggesting its potential use in treating thrombotic or cardiovascular diseases.
Insights
Setanaxib, a dual NADPH oxidase (NOX) inhibitor, effectively reduces reactive oxygen species (ROS) production and collagen-induced platelet activation. This dual NOX1/4 inhibitor shows potential for treating thrombotic and cardiovascular diseases.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- NADPH oxidase (NOX) enzymes generate reactive oxygen species (ROS), which are key mediators of platelet activation.
- Platelet activation by NOX presents a potential therapeutic target for antiplatelet strategies.
Purpose of the Study:
- To investigate the effects of setanaxib, a dual NOX1/4 inhibitor, on human platelet function and associated ROS-dependent signaling pathways.
- To evaluate the anti-thrombotic potential of setanaxib in vitro and in vivo.
Main Methods:
- Human platelets were stimulated with collagen, and responses were measured using aggregometry, ROS and Ca2+ assessment, immunoblotting, ELISA, and flow cytometry.
- Platelet adhesion assays and mouse arterial thrombosis models were employed to assess thrombus formation.
- Key signaling molecules including Syk, LAT, Vav1, Btk, PLCγ2, PKC, p38 MAPK, and ERK5 were analyzed.
Main Results:
- Setanaxib significantly inhibited both intracellular and extracellular ROS production in activated platelets.
- Setanaxib suppressed collagen-induced platelet aggregation, degranulation (P-selectin and ATP release), and integrin αIIbβ3 activation.
- Setanaxib blocked critical signaling cascades, including Syk, LAT, Vav1, Btk, PLCγ2, PKC, Ca2+ mobilization, p38 MAPK, and ERK5 pathways, thereby reducing procoagulant phosphatidylserine exposure.
- Setanaxib inhibited platelet adhesion to collagen and reduced thrombus formation under shear conditions.
- In vivo, setanaxib administration effectively inhibited arterial thrombosis in animal models.
Conclusions:
- Setanaxib demonstrates potent antiplatelet and anti-thrombotic effects by inhibiting NOX-dependent ROS generation and downstream signaling pathways.
- These findings highlight setanaxib as a promising therapeutic agent for managing thrombotic disorders and cardiovascular diseases.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:23Antihypertensive Drugs: Vasodilators